• understanding DNA, dna sequencing, ARK research, human genomw

    Understanding DNA, the Human Genome, and the Rise of CRISPR

    by | Health

    In fewer than five years, Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR genome-editing technology, has taken the scientific community by storm, not only revolutionizing the pace of biological breakthroughs but also promising medicines that cure diseases now considered incurable. Please enjoy a primer to assist in understanding DNA, the human genome, and the rise of […]

  • gene therapies

    Gene Therapy Invites Competition

    by | Health
    Mentioned Companies: GILD, KITE

    The debate over drug pricing has intensified significantly after the recent approval of two CAR-T therapies, Kymriah and Yescarta. CAR-T is a type of gene therapy that harnesses a patient’s immune system to attack and kill cancer cells, providing a potential cure for metastatic cancer. Kymriah was the first CAR-T approved, for pediatric acute lymphoblastic […]

  • CRISPR-vs.-TALENs Banner

    Gene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs

    by | Health
    Mentioned Companies: CRSP, EDIT, NTLA

    Genome-Editing During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in biotechnology and synthetic biology: now research is focused not on “treatment” of diseases but on its modification and cure.  The ability to directly edit living cells has brought gene therapy and precision medicine into […]

  • Colorectal Cancer Banner

    Molecular Diagnostic Tests Could Be a Lifesaver for Colorectal Cancer Patients

    by | Health
    Mentioned Companies: EXAS, VNRX

    A molecular diagnostic test for colorectal cancer could lower the age at which testing makes economic sense, an important consideration for a disease increasingly prevalent in younger people. As ARK has documented previously, early diagnosis could have a more profound impact on cancer care than could any of the promising next-generation treatments in the pipeline. […]

  • Stem Cell Banner

    The Stem Cell Revolution

    by | Health
    Mentioned Companies: BAYRY, BIIB, CRSP, EDIT, GSK, NTLA, NVS

    Discovered nearly thirty years ago in 1988[1], stem cell technology has failed to transform the field of regenerative medicine…until no­­w. After delivering only one treatment during three decades of development, stem cell technology could finally become the all-purpose tool for repairing the body, thanks to rapid and precise genome editing techniques such as CRISPR and […]

  • alzheimer's treatment

    Alzheimer’s: Solving a Major Unmet Need

    by | Health
    Mentioned Companies: ACIU, AVXL, BIIB

    An Alzheimer’s treatment that converts the neurodegenerative disease from a cruel killer into a tolerable chronic condition could become the best selling drug in history.1 According to ARK’s estimates, the annual revenue associated with an effective Alzheimer’s treatment could approximate to $120 billion USD.2 While many companies have attempted to develop an effective treatment, not one has […]

  • Early Cancer Diagnostics

    Could Liquid Biopsies Be The Holy Grail in Cancer Diagnostics?

    by | Health

    Next generation genetic tests aim to provide cancer diagnostics at a very early stage, potentially saving millions of lives per year and generating hundreds of billions in revenue. Given the pace of improvement in their specificity and reliability, molecular diagnostic tests could make more progress against cancer in the next decade than have all the […]

  • CRISPR Gene Editing

    The CRISPR Gene Editing Approach to Treating and Curing Diseases

    by | Health

    The Promise DNA (Deoxyribonucleic acid) is the “source code” of life, and now we can edit and correct that code efficiently and cost-effectively should there be a disease-causing error. In other words, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)[1] gene editing could save millions of lives and cure thousands of genetic disorders, if it is to […]

  • deep learning based diagnostic, deep learning based radiology, ai, ark research, innovation research

    Deep Learning Based Diagnostics: Unlocking a $16 Billion Market

    by | Digital Health
    Mentioned Companies: IBM

    Intelligent software could “eat” into diagnostic radiology, just as it has eaten countless other industries. We think the result, deep learning based diagnostics software, will likely lead to faster, cheaper, and more accurate diagnoses on a global scale. The key enabling technology is deep learning, a form of artificial intelligence (AI) that has established benchmarks […]

  • blockchain technology, ark research, blockchain health care, blockchain ehr, innovation research, invest in innovation,

    How Blockchain Technology Can Enhance Electronic Health Record (EHR) Operability

    by | Health White Paper

    In healthcare, information is not only private, it is proprietary. While doctors and patients yearn for a digital and unified patient health record, the infrastructure required to accomplish this doesn’t exist yet. A blockchain could be a public catalog of health records that references databases, fitness and medical devices, mobile phones, and laptops. It could […]

  • health care innovation, drug approval, Companion Diagnostics, cdx, ark research,

    Companion Diagnostics (CDx): More Drugs At A Fraction Of The Cost

    by | Health
    Mentioned Companies: ABBV, AZN, FMI, ILMN, MYGN, NSTG, NVTA

    Prime Time for Companion Diagnostics We think the drug approval process remains convoluted, costly, and time-consuming, but it is about to change. The increased adoption of Companion Diagnostics (CDx)—tests that identify the most suitable patients for a particular treatment—holds much promise. ARK expects that CDx will improve patient outcomes demonstrably, reduce research and development spending […]

  • illumina, dna sequencing, ILMN stock, ark research, ark invest, invest in ilmn

    Illumina Is the Bedrock of the Genomic Revolution

    by | Health
    Mentioned Companies: ILMN

    Illumina  is the cornerstone of our Genomic Revolution theme, and one of our highest conviction stocks.  In response to an earnings preannouncement this week, it dropped as much as 25% in one day.  While investors fear that it has passed its fastest growth rate, in our view Illumina is leading a genomic revolution that has […]

  • Zika Virus, Zika Virus research

    Will Cerus INTERCEPT Prevent the Transmission of the Zika Virus?

    by | Health
    Mentioned Companies: CERS, INO, NLNK, XON

    Amid a global epidemic, the Food and Drug Administration (FDA) has issued new guidelines for blood banks to prevent the contamination and transmission of the Zika virus. While whole blood donations are banned in Zika-endemic parts of the world, Cerus INTERCEPT would enable the safe collection and transfusion of plasma and platelets. Two years after […]

  • Alex Cahana, Theme Developer, ARK Invest, Interview, Healthcare, Biotechnology

    How Has The Health Care System Changed? An interview with Dr. Alex Cahana

    by | Health

    In an age of proliferating targeted drugs, plummeting DNA sequencing costs, and skyrocketing prices, many people have an answer to the question, “What’s wrong with healthcare?” Physician, Veteran, and ARK Theme Developer Alex Cahana has a stunning answer: “We don’t care about health.” In a 40 minute interview, Dr. Cahana talks about his experience in the […]

  • Sovaldi, Research, Genomic Revolution, Thematic Investing, ARK Invest

    A Bitter Pill: The High Cost of Sovaldi

    by | Health
    Mentioned Companies: ABBV, CVS, ESRX, GILD

    It’s almost impossible to imagine a pharma company giving up on a patent. The impossible can happen, as it did in August 2014, when Vertex Pharmaceuticals gave up on Incivek, its flagship hepatitis C treatment. “This decision has been taken in view of available alternative treatments and the diminishing market demand for Incivek,” read a […]

  • site cancer tests, Cancer, On-site Diagnosis, lab, ARK, ARK Invest

    On-site Cancer Tests Can Increase Survival Rates

    by | Health
    Mentioned Companies: CPHD, FMI, GHDX, MYGN

    Patients with pancreatic cancer have a 35% chance of dying before their molecular diagnostic test results return from the lab. At roughly a 23-29% chance, lung, brain, and stomach cancer patients have only marginally better odds of surviving to see the results, as shown below. Precision medicine enables personalized diagnoses and directs molecular treatments. Companies […]

  • biosimilars, biologics, generics, cost, pharma, ark genome, genomic revolution, ARKG, Ark invest.

    Biosimilars vs Generics: History Does Not Repeat, It Rhymes

    by | Health
    Mentioned Companies: AMGN, BIIB, CELG, ESRX, MRK, NVS, ORINY

    Healthcare investors likely remember the devastating impact of generic drugs on drug prices in the late 1980s. While traditional firms struggled, many successful biotechnology companies took root during this turbulent period. Focusing on the growing field of biologic medicine, many biotech firms were acquired by pharmaceutical companies looking to lower research and development costs, while […]

  • Cepheid, ark research, cancer detection, innovation

    Cancer Detection Could be Faster and Cheaper with Cepheid’s New Test

    by | Health
    Mentioned Companies: ABT, CPHD, FMI, GHDX, MYGN

    Today, the detection of cancer is time consuming and expensive. Tissue samples from molecular diagnostic tests must be mailed to a lab and sequenced or otherwise analyzed. In the United States, the process can take between seven and fourteen days, and costs $4,000 to $8,000. Test results from Foundation Medicine , Myriad Genetics , and […]

  • immunotherapy, ark research, health care research, invest in health care

    Immunotherapy: Unleashing the Immune System to Decimate Cancer

    by | Health
    Mentioned Companies: AMGN, BMY, JUNO, KITE, MRK, NVS

    For more than a century, surgery and poison have been the antidotes to cancer. When tumors are discovered, doctors decide whether or not to remove them surgically. With or without surgery, doctors typically prescribe chemotherapy in an attempt to eradicate the disease chemically. Immunotherapy is the most heralded cancer treatment of the last 20 years, offering […]

  • zafgen, obesity, pharamceutical, genomic revolution, arkg, arkgenome, pharmaceutical innovation,

    Zafgen Offers Hope For The Obese

    by | Health
    Mentioned Companies: ZFGN

    It is no secret that obesity is linked to health risks. Obesity is associated with a higher risk of cancer, diabetes, heart disease, and stroke, as well as the psychological effects from discrimination and the stigma. Weight is not the only excess, however. Spending is as well. Zafgen might have an answer. Obese individuals spend on […]